Under the leadership of Dr. You, who was appointed CEO in January 2019, Amunix has focused its internal efforts on advancement of the XPAT and XPAC platforms and the company’s proprietary pipeline. He was also responsible for all domestic and international clinical trial contracts, as well as informed consent form reviews. His doctoral work, performed in the laboratory of Dr. Arthur Weiss, pioneered the single-chain chimeric antigen receptor (CAR) technology. View Deena Rennerfeldt’s profile on LinkedIn, the world's largest professional community. Prior to Morgan Stanley, Mr. Company profile page for Amunix Operating Inc including stock price, company news, press releases, executives, board members, and contact information ... Dr Angie You… Anne is an experienced regulatory leader with extensive experience across numerous therapeutic areas and phases of development. Dr. Bryan Irving currently serves as the Chief Scientific Officer of Amunix. Anne Keane, J.D. She also led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. ... Dr Angie You… in Biology from Duke University and a Ph.D. in Biochemistry from Harvard University. Prior to joining Amunix, Dr. She earned a B.S. Angie You, Ph.D., Chief Executive Officer at Amunix, said, "The completion of our Series A financing marks a critical milestone for Amunix, as the investment affords us a significant financial runway to advance our novel pipeline of T cell engagers and cytokines targeting a spectrum of solid tumors. Angie You is Chief Executive Officer at Amunix Inc. See Angie You's compensation, career history, education, & memberships. Dr. Hora has served the biopharmaceutical industry for more than 30 years with demonstrated leadership in process, analytical and pharmaceutical sciences, manufacturing and quality functions. Angie You, Amunix Pharmaceuticals. www.amunix.com. Prior to Ayer Capital, Mr. Amunix Chief Executive Officer Angie You, who took over that role last year, said the completion of the Series A financing round is a critical milestone for the company. Amunix to receive $40 million in upfront payment and may receive up to $1.5 billion in development and sales milestones; Roche to utilize XTEN, Amunix’s clinically validated therapeutic half-life extension technology, to discover and develop novel therapeutics ; MOUNTAIN VIEW, CA; January 10, 2020 – Amunix Pharmaceuticals, Inc. (“Amunix”), a … After postdoctoral studies at the Institute for Protein Research in Pushchino (Russia), he moved to the University of Göttingen where he developed a novel method for the production of peptides from recombinant peptide-multimers. You, who was appointed CEO in January 2019, Amunix has focused its internal efforts on advancement of the XPAT and XPAC platforms and the company’s proprietary pipeline. Dr. Mootz started her career in industry at L.E.K. 2011. She has deep expertise in oncology drug development, which spans multiple therapeutic modalities, tumor types, and all phases of development. Before joining Amunix, Robert served as Senior Director of Contracts at Sierra Oncology, where he negotiated manufacturing, collaboration, and clinical supply agreements, and managed CRO contract-related issues. To access all the content for free, please sign up by entering your email. He has been part of teams that have successfully filed 50+ INDs and registered 11 biopharmaceutical products worldwide. NO. Prior to joining Amunix, Dr. Amunix … “We are excited to welcome Zeeshan and Trisha, both leaders in the financial services and healthcare industry, to Amunix,” said Angie You, CEO of Amunix. We look forward to providing you with even more cutting-edge market research, as Topio Networks. Prior to joining Amunix, Ursula served as Clinical Program Director at Genentech, leading multiple programs from entry into the clinic into phase three development, including taselisib and GDC-9545. In this role, Mr. You, who was appointed CEO in January 2019, Amunix has focused its internal efforts on advancement of the XPAT and XPAC platforms and the company’s proprietary pipeline. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures. He brings over 18 years of extensive contract negotiation experience in both small and large companies, including Sierra Oncology, Pharmacyclics, Gilead, and Abbott Vascular. Dr. Mootz is the Chief Business Officer of Amunix. From Angie, Amunix CEO: I’m sorry to hear that you would not recommend Amunix. She also led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. View Amunix Pharmaceuticals (www.amunix.com) location in California, United States , revenue, industry and description. Prior to that, she spent 20 years working at a law firm specifically focused on intellectual property law as it applies to the biopharmaceutical industry, as well as advising clients on related regulatory and legislative changes in fast-evolving legal markets. Stemmer and Volker Schellenberger in 2006 and is headqua Tue, Jan 08, 2019 by Spoke Tech . The Company focuses on therapeutic drugs which offer an alternative to antibodies and small molecules. Zeeshan Merchant. In addition, he initiated and led collaborations with Seattle Genetics that focused on antibody-enzyme fusion proteins. The company was founded by Willem P.C. Prior to that, she served as Chief Business Officer of ORIC Pharmaceuticals, then an early-stage oncology company, where she had a broad operational role. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. Dr. Irving received his Ph.D in Immunology from the University of California, San Francisco, and a B.A. Angie You, Ph.D., Chief Executive Officer at Amunix, said, "The completion of our Series A financing marks a critical milestone for Amunix, as the investment affords us a significant financial runway to advance our novel pipeline of T cell engagers and cytokines targeting a spectrum of solid tumors. Before joining the company, she was an independent consultant working with VCs and pharmaceutical companies on a wide range of corporate development and strategy projects, including new company formation, product launch strategy, and M&A strategy. “We are excited to welcome Zeeshan and Trisha, both leaders in the financial services and healthcare industry, to Amunix,” said Angie You, CEO of Amunix. She is an accomplished drug developer with over 25 years of experience in cancer research, including a 15-year career at Genentech/Roche. In previous roles, Dr. You served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals. Angie You, CEO. Ursula is a seasoned clinical operations leader with over 20 years of global clinical development experience across a number of established and emerging biotech and pharmaceutical companies including Genentech, Exelixis, Astex, and QLT Inc. She has led global clinical operations programs spanning a variety of therapeutic areas and all phases of clinical development, contributing to over 20 programs and subsequent multiple regulatory approvals at both small and large biotech companies. Angie You is the CEO of Amunix Pharmaceuticals, Inc. and is a member of the Council of Korean Americans since 2020. Menu BY DISEASE BY TECHNOLOGY BY COUNTRY. Install the Alexa Browser Extension to get free competitive intelligence about millions of websites while you browse the web. Under the terms of the deal, Roche will pay Amunix $40 million upfront. While at Achaogen, Anne led the regulatory and clinical quality organizations through the development and approval of Zemdri®, an important new antibiotic for gram negative infections. While VP of Corporate Development at Achaogen, she helped the company complete a successful IPO, led the project team for the company’s lead Phase 3 antibiotic (now launched as ZEMDRI), and helped raise over $200M in capital. After a postdoctoral fellowship with Bill Rutter at the University of California, San Francisco, Dr. Schellenberger joined Genencor in 1994. Chief Commercial Strategy Officer of SAGE Therapeutics, Chief Commercial Officer of JenaValve Technology, Chief Business Officer of Mersana Therapeutics, R&D in Biotech, Environmental and various industries (no marketing product yet), Chief Business & Strategy Officer & Head of Commercial, Chief Business and Strategy Officer, Head of Commercial, Intelligent Assistance and Bots Ecosystem. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. “Their expertise and leadership will be invaluable as we continue to grow Amunix and transition into a … She also served as the Co-Chair of the Cancer Immunotherapy Committee (CITC), the GI/GU Franchises Committee, and the Breast Cancer Disease Area Team. Prior to Sierra, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, human resources, and business development. Robert Jones serves as the Vice President of Contracts at Amunix. Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics, today announced the appointment of Angie You, Ph.D., as Chief Executive Officer, and Rich Heyman, Ph.D., as Chairman of the Board of Directors. We are excited about the potential of our lead development candidate, AMX-818, a protease … Dr. Nabeela Rasheed serves as the Vice President for Intellectual Property at Amunix. Chief Financial Officer. is the Senior Vice President of Regulatory and Quality. Angie You, Ph.D. Chief Executive Officer. Partnering. Angie serves as Chief Executive Officer of Amunix Pharmaceuticals Inc. Biologic immune activators hold tremendous untapped promise to help many cancer patients achieve better outcomes,” Amunix CEO Angie You said in a statement. Amunix Pharmaceuticals Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics, today announced the appointment of Angie You, Ph.D., as Chief Executive Officer, and Rich Heyman, Ph.D., as Chairman of the Board of Directors. For additional information about the company, please visit www.amunix.com. We understand that … Last year, Amunix brought on Frazier Life Sciences as majority shareholder and appointed Dr. Angie You as CEO. In this role, Mr. Angie You. Ursula received a Master of Arts degree from Simon Fraser University and a certificate in Biotechnology, Clinical Trial Design and Management from San Francisco State University. Prior to joining Amunix, Mr. Angie You works as the CEO at Amunix Pharmaceutical. She has over 25 years of experience in drug discovery and development, with expertise extending from high throughput screening and drug discovery, to clinical development (IND to phase III), regulatory filings, and market access. “We continue to be excited by progress of AMX-818 and its strong efficacy and safety data package,” said Angie You, Ph.D., CEO of Amunix. Dr. Shankar received a Ph.D. in Molecular Pharmacology from Northwestern University School of Medicine and an M.S. Country: USA | Funding: $73M | link Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics. Dr. Derynck was also a Senior Group Medical Director of Exploratory Clinical Development at Genentech, serving as the development lead for multiple early-stage programs. Dr. Derynck is the Chief Medical Officer of Amunix. “We are excited to welcome Anne, a regulatory leader with significant experience across all phases of development, to Amunix,” said Angie You, CEO of Amunix. Earlier experience includes leading successful regulatory filings for Avastin® and Perjeta®. Merchant worked as a private equity Associate at TA Associates, a leading, global growth private equity firm. “Their expertise and leadership will be invaluable as we continue to grow Amunix and transition into a clinical stage company. 1 Rating. She also brings significant partnership and alliance management experience. Angie You, CEO Country: USA | Funding: $73M | link Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics. Prior to joining Amunix, he served as Chief Scientific Officer of Five Prime Therapeutics, where he led research and preclinical drug development, and as Vice President of Cancer Immunology at CytomX Therapeutics, where he led immune applications of their protease-activatable, prodrug technology (included T cell bispecifics and T cell checkpoint targets). Dr. Maninder Hora currently serves as the Chief Technical Operations Officer of Amunix. “New in vivo results demonstrating AMX-818 efficacy in a HER2-low tumor model support the potential to treat the significant population of patients with HER2-low and –medium tumors who are not currently served by any HER2 … Chief Executive Officer. Angie serves as Chief Executive Officer of Amunix Pharmaceuticals Inc. Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche.Amunix has had previous licensing deals with Johnson & Johnson, Genentech, Merck and Biogen.Its technology has previously focused on extending the half-life of drugs.. The funding from the round provides Amunix with a “significant financial runway” to advance its novel pipeline against solid tumors. Apr. Previously, he headed the Protein Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by micro-compartmentalization, as well as mutator technology. Biographies les plus recherchées chez Amunix. Ursula McCurry serves as the Vice President of Clinical Operations at Amunix. In the latter function, she worked on early trials for cabozantinib in medullary thyroid cancer. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology (NASDAQ: SRRA), a publicly listed hematology and oncology drug development company, where she helped the company through a successful … Senior Vice President of Regulatory and Quality, Vice President of Clinical Science and Clinical Operations. Amunix Signs Research Collaboration With Biogen Idec for Next Generation Long-Lasting Blood Factor Products - Yahoo! Angie You, Ph.D. Chief Executive Officer. Angie You, Ph.D. Chief Executive Officer. Merchant worked as Senior Analyst at Ayer Capital, a healthcare dedicated investment fund. “We continue to be excited by progress of AMX-818 and its strong efficacy and safety data package,” said Angie You, Ph.D., CEO of Amunix. About Dr. Angie You, Chief Executive Officer Prior to joining Amunix, Dr. Contacts: Angie You, Ph.D. CEO Tel: 650-889-5095 ayou@amunix.com amunix logo.jpg Published on May 14, 2019, 8:05 AM EDT
Minecraft Addons Not Working,
Assistant Chief Interview Questions,
Alas Nothing Happened Ds2 Shrine Of Amana,
Philippines Zip Code List,
Nordictrack C990 Reset Button,
Twa Hotel Cars,